Pasar al contenido principal

ESTUDIOS IN VITRO E IN VIVO DE NUEVOS NANOVEHICULOS PARA TERAGNOSTICA DE ENFERMEDADES CEREBRALES

RTI2018-098027-B-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining experimental and computational tools to unravel copper-based metallodrug interactions with proteins

  • Peña Aparicio, Joaquim|||0000-0001-6477-8127
  • Zapirain Gysling, Iker|||0000-0001-5117-7082
  • Simaan, A. Jalila|||0000-0003-2537-0422
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Iranzo, Olga|||0000-0001-8542-2429
  • Palacios, Òscar|||0000-0002-2987-7303
  • Maréchal, Jean-Didier|||0000-0002-8344-9043
  • Bayón, Pau|||0000-0002-3064-8866
Metallodrugs are widely used in the treatment of several diseases, including cancer. Many bloodstream proteins exhibit high affinities for metals and metal-based compounds, and these interactions have been shown to impact metallodrug pharmacokinetics and pharmacodynamics, ultimately influencing their therapeutic performance. Several spectroscopic, spectrometric, and computational techniques have been used to further understand drug-protein binding modes at the molecular level over the last few years. However, there is still plenty of room to ascertain the full potential of integrated experimental-computational methodologies in the field of metallodrugs. These studies have mostly been limited to a few metal-containing systems, such as platinates and vanadium drugs. In this work, we aim to expand and validate the use of combined experimental-theoretical approaches in studying copper (Cu)-based drug interactions with proteins. To do so, a tetracoordinated Cu(II) complex has been employed as a practical case study, and its interactions with several relevant proteins using different experimental and computational techniques have been evaluated, including electron paramagnetic resonance spectroscopy, mass spectrometry, density functional theory, and protein-ligand docking calculations. Experimental data highlight interactions of the Cu(II) complex with albumin, myoglobin, and cytochrome C. Further insights into the preferential modes of binding were evaluated by density functional theory and docking calculations, which revealed three main outer surface binding sites for both albumin and myoglobin, as well as three preferential inner pockets in the case of albumin. The most relevant binding modes found for both proteins include noncoordinative interactions with the Cu(II) dimeric structure intact upon binding, as well as metal-ligand exchange and direct metal-amino acid coordination, mainly to glutamate/aspartate residues after cleavage of the dimer. Altogether, an example of the applicability of a mixed experimental-theoretical framework in the study of Cu-based drug interactions with relevant proteins is shown.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Surface engineering of silica nanoparticles with a gadolinium-PCTA complex for efficient T1-weighted MRI contrast agents

  • Mathieu, Paul|||0000-0002-1663-3860
  • Chalet, Marie
  • Clain, Marie Myriam
  • Teulon, Lauryanne
  • Benoist, Eric
  • Leygue, Nadine
  • Picard, Claude|||0000-0002-8770-7732
  • Boutry, Sébastien
  • Laurent, Sophie|||0000-0002-2589-3250
  • Stanicki, Dimitri
  • Henoumont, Céline
  • Novio, Fernando|||0000-0002-1517-3612
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Montpeyó, David|||0000-0002-0327-2015
  • Ciuculescu-Pradines, Diana|||0000-0002-7953-232X
  • Amiens, Catherine|||0000-0002-9088-1635
New pyridine containing triAza; 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA) ligands presenting pendant carboxylic acid or alcohol functions have been synthesized and used to form diaqua Gd(iii) complexes, which have been immobilized onto dense silica nanoparticles. Cytotoxicity studies of these complexes (free or immobilized on the nanoparticles) on normal 1BR3G cells and cancerous HCT 116 cells indicated a dependence on the pendant chemical group for the free complexes. However, this effect disappeared once the complexes were immobilized on the surface of the nanoparticles, leading to non-toxic nanomaterials. The interest of these complexes (free or immobilized on dense silica nanoparticles) as contrast agents in magnetic resonance imaging (MRI) has been evaluated in comparison with DOTAREM® by recording their nuclear magnetic resonance dispersion (NMRD) profiles, measuring their transversal and longitudinal relaxivities as well as recording images on phantoms at 37 °C. This study has evidenced the high potential of these complexes: first it suggested the possibility to reduce the dose to be injected by a factor of 10, second it evidenced their high efficiency in high field T1-weighted MRI (9.4 T), the key towards images of higher resolution and shorter acquisition times.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Luminescent silicon-based nanocarrier for drug delivery in colorectal cancer cells

  • Marcelo, Gonçalo A.
  • Montpeyó, David
  • Novio, Fernando
  • Ruiz Molina, Daniel
  • Lorenzo, Julia
  • Oliveira, Elisabete
Nanocarriers sensitive to exogenous or endogenous stimuli emerged as an attractive alternative to target drug delivery, with inorganic silica mesoporous nanoparticles (MNs) playing a core role in the development of a new generation of non-toxic and tuneable nanocarriers. A sensitive nanovector (NANO1) comprising luminescent silicon quantum dots (SiQDs) and functionalized with MNs was synthesised and loaded with doxorubicin (DOX). NANO1 nanoparticles have a size of 74 ± 10 nm and DOX loading percentages of ca. 43%. As a control sample, a similar nanocarrier (NANO2), without SiQDs, was also synthesised and loaded with DOX. Release profile studies, in PBS, revealed the strong NANO1@DOX pH-dependant behaviour, with a pH 5.0 favouring the release of DOX to percentages of ca. 70%. Cytotoxicity assessments of both free and DOX-loaded nanocarriers were evaluated in human cell lines of colon, revealing both free drug and drug-loaded nanoparticles to be concentration-dependent., This work was supported by the Associate Laboratory Research Unit for Green Chemistry - Clean Processes and Technologies - LAQV which is financed by national funds from FCT/MEC (UID/QUI/50006/2013) and co-financed by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER- 007265); by the Scientific Society PROTEOMASS (Portugal) (General Funding Grant) and by the Spanish Ministry of Science, Innovation and Universities project RTI2018-098027-B-C22. This work was also supported by grant RTI2018-098027-B-C21 and RTI2018-088027-B-C22 from the Spanish Government funds and by the European Regional Development Fund (ERDF). The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). F. N thanks to COST Action CA17121. F. N and J. L thanks to COST Action CA15138. G.M thanks to FCT/MEC (Portugal) for his doctoral grant PD/BD/142865/2018. E. O thanks FCT/MEC (Portugal) for the individual contract, CEECIND/00648/2017., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Time‐dependent cytotoxic properties of terpyridine‐based copper complexes

  • Grau, Jordi
  • Caubet, Amparo
  • Roubeau, Olivier
  • Montpeyó, David
  • Lorenzo, Julia
  • Gamez, Patrick
Five copper complexes supported by terpyridine ligands were prepared and characterized, viz. [Cu3Cl4(naphtpy)2][CuCl2] (1), [Cu2Cl2(naphtpy)2](ClO4)2 (2), [CuCl2(naphtpy)]2(MeOH)3(H2O) (3), [CuCl2(Cltpy)] (4) and [Cu(Cltpy)2](ClO4)2 (5); (where naphtpy stands for 4’‐((naphthalen‐2‐yl)methoxy)‐2,2′:6′,2′′‐terpyridine and Cltpy for 4′‐chloro‐2,2′:6′,2′′‐terpyridine). Their ability to interact with DNA was investigated, and their cytotoxic behaviour was examined with three cells lines, namely human ovarian carcinoma cells (A2780), their derived cisplatin‐resistant line (A2780cis), and human cervix adenocarcinoma cells (HeLa). All compounds show good cytotoxic properties (especially after 72 h of incubation). Remarkably, two compounds, 4 and 5, are still almost inactive after 24 h (particularly 4), but are highly active after 72 h, with IC50 values in the low‐micromolar to sub‐micromolar range. Compounds 1 and 2 induce necrosis, whereas late apoptosis is observed with 3–5, 4 exhibiting a behaviour close to that of cisplatin., Financial support from the Spanish Ministerio de Ciencia Innovación, y Universidades (Projects CTQ2017‐88446‐R AEI/FEDER, UE, RED2018‐102471‐T and RTI2018‐098027‐B‐C22) is kindly acknowledged. P.G. acknowledges the Institució Catalana de Recerca i Estudis Avançats (ICREA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in parkinson's disease

  • García-Pardo, Javier
  • Novio, Fernando
  • Nador, Fabiana
  • Cavaliere, Ivana
  • Suárez-García, Salvio
  • Lope-Piedrafita, Silvia
  • Candiota, Ana Paula
  • Romero-Giménez, Jordi
  • Rodríguez-Galván, Beatriz
  • Bové, Jordi
  • Vila, Miquel
  • Lorenzo, Julia
  • Ruiz Molina, Daniel
Dopamine (DA) is one of the main neurotransmitters found in the central nervous system and has a vital role in the function of dopaminergic (DArgic) neurons. A progressive loss of this specific subset of cells is one of the hallmarks of age-related neurodegenerative disorders such as Parkinson's disease (PD). Symptomatic therapy for PD has been centered in the precursor l-DOPA administration, an amino acid precursor of DA that crosses the blood-brain barrier (BBB) while DA does not, although this approach presents medium- to long-term side effects. To overcome this limitation, DA-nanoencapsulation therapies are actively being searched as an alternative for DA replacement. However, overcoming the low yield of encapsulation and/or poor biodistribution/bioavailability of DA is still a current challenge. Herein, we report the synthesis of a family of neuromelanin bioinspired polymeric nanoparticles. Our system is based on the encapsulation of DA within nanoparticles through its reversible coordination complexation to iron metal nodes polymerized with a bis-imidazol ligand. Our methodology, in addition to being simple and inexpensive, results in DA loading efficiencies of up to 60%. In vitro, DA nanoscale coordination polymers (DA-NCPs) exhibited lower toxicity, degradation kinetics, and enhanced uptake by BE(2)-M17 DArgic cells compared to free DA. Direct infusion of the particles in the ventricle of rats in vivo showed a rapid distribution within the brain of healthy rats, leading to an increase in striatal DA levels. More importantly, after 4 days of nasal administrations with DA-NCPs equivalent to 200 μg of the free drug per day, the number and duration of apomorphine-induced rotations was significantly lower from that in either vehicle or DA-treated rats performed for comparison purposes. Overall, this study demonstrates the advantages of using nanostructured DA for DA-replacement therapy., This work was supported by grants RTI2018-098027-B-C21 and RTI2018-098027-B-C22 from the Spanish Government funds and by the European Regional Development Fund (ERDF). The ICN2 is funded by the CERCA program/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence program, funded by the Spanish Research Agency (AEI, grant no. SEV-2017-0706). M.V. received funding from “la Caixa” Foundation (ID 1178 100010434, under the agreement LCF/PR/HR17/52150003) 1179, Ministry of Economy and Competitiveness (MINECO, Spain) (SAF2016-77541-R) and The Michael J. Fox Foundation for Parkinson’s Research 1180 (Grant ID: 15291.01). A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222. The authors thank the support from COST Action CA17121.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

  • Ruiz Molina, Daniel
  • Mao, Xiaoman
  • Alfonso Triguero, Paula
  • Lorenzo, Julia
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Candiota, Ana Paula
  • Novio, Fernando
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22, and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033, by ERDF A way of making Europe and by PI21/00181 from the Instituto Carlos III. This work was also supported by “Metalfármacos multifuncionales para el diagnóstico y la terapia”, through grant RED2018-102471-T, funded by MCIN/AEI/10.13039/501100011033. The ICN2 and IDIBELL are funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, grant SEV-2017-0706, funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222. This work was also supported by the Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy

  • Mao, Xiaoman
  • Calero Pérez, Pilar
  • Montpeyó, David
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Candiota, Ana Paula
  • Lorenzo, Julia
  • Novio, Fernando
  • Ruiz Molina, Daniel
Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH-and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22 and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe. With the support from “Metalfármacos multifuncionales para el diagnóstico y la terapia” with grant RED2018-102471-T funded by MCIN/AEI/10.13039/501100011033. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, grant SEV-2017-0706 funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222. Work also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en, accessed on 24 March 2022], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship. We acknowledge the UAB Predoctoral training program (14ª Convocatoria PIF-19612, predoctoral fellowships for P.C.-P)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

  • Mao, Xiaoman
  • Wu, Shuang
  • Calero Pérez, Pilar
  • Candiota, Ana Paula
  • Alfonso Triguero, Paula
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Lorenzo, Julia
  • Novio, Fernando
  • Ruiz Molina, Daniel
Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood–brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood–brain barrier. Thus, herein we report the synthesis and study of complex 1, a Pt(IV) prodrug functionalized with catecholic moieties. This complex considerably augmented solubility in contrast to cisplatin and showed a comparable cytotoxic effect on cisplatin in HeLa, 1Br3G and GL261 cells. Furthermore, preclinical in vivo therapy using the intranasal administration route suggested that it can reach the brain and inhibit the growth of orthotopic GL261 glioblastoma. These results open new opportunities for catechol-bearing anticancer prodrugs in the treatment for brain tumors via intranasal administration., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22 and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF’s A way of making Europe as well as with the support from “Metalfármacos multifuncionales para el diagnóstico y la terapia” with grant RED2018-102471-T funded by MCIN/AEI/10.13039/501100011033. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, and grant SEV-2017-0706 is funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under grant agreement 777222. The work was also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en, accessed on 24 November 2021], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship. We acknowledge the UAB predoctoral training program (14th Convocatoria PIF-19612, predoctoral fellowships for P.C.-P) and China Scholarship Council (predoctoral fellowship 201606990027 for S.W.).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Time-Dependent Cytotoxic Properties of Terpyridine-Based Copper Complexes

  • Grau, J.
  • Caubet, A.
  • Roubeau, O.
  • Montpeyó, D.
  • Lorenzo, J.
  • Gamez, P.
Five copper complexes supported by terpyridine ligands were prepared and characterized, viz. [Cu3Cl4(naphtpy)2][CuCl2] (1), [Cu2Cl2(naphtpy)2](ClO4)2 (2), [CuCl2(naphtpy)]2(MeOH)3(H2O) (3), [CuCl2(Cltpy)] (4) and [Cu(Cltpy)2](ClO4)2 (5); (where naphtpy stands for 4’-((naphthalen-2-yl)methoxy)-2, 2':6', 2''-terpyridine and Cltpy for 4'-chloro-2, 2':6', 2''-terpyridine). Their ability to interact with DNA was investigated, and their cytotoxic behaviour was examined with three cells lines, namely human ovarian carcinoma cells (A2780), their derived cisplatin-resistant line (A2780cis), and human cervix adenocarcinoma cells (HeLa). All compounds show good cytotoxic properties (especially after 72 h of incubation). Remarkably, two compounds, 4 and 5, are still almost inactive after 24 h (particularly 4), but are highly active after 72 h, with IC50 values in the low-micromolar to sub-micromolar range. Compounds 1 and 2 induce necrosis, whereas late apoptosis is observed with 3–5, 4 exhibiting a behaviour close to that of cisplatin.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Silica coated iron/iron oxide nanoparticles as a nano-platform for T2 weighted magnetic resonance imaging

  • Mathieu, Paul|||0000-0002-1663-3860
  • Coppel, Yannick|||0000-0003-0970-4082
  • Respaud, Marc
  • Nguyen, Quyen T.
  • Boutry, Sébastien
  • Laurent, Sophie|||0000-0002-2589-3250
  • Stanicki, Dimitri
  • Henoumont, Céline
  • Novio, Fernando|||0000-0002-1517-3612
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Montpeyó, David|||0000-0002-0327-2015
  • Amiens, Catherine|||0000-0002-9088-1635
The growing concern over the toxicity of Gd-based contrast agents used in magnetic resonance imaging (MRI) motivates the search for less toxic and more effective alternatives. Among these alternatives, iron-iron oxide (Fe@FeOx) core-shell architectures have been long recognized as promising MRI contrast agents while limited information on their engineering is available. Here we report the synthesis of 10 nm large Fe@FeOx nanoparticles, their coating with a 11 nm thick layer of dense silica and functionalization by 5 kDa PEG chains to improve their biocompatibility. The nanomaterials obtained have been characterized by a set of complementary techniques such as infra-red and nuclear magnetic resonance spectroscopies, transmission electron microscopy, dynamic light scattering and zetametry, and magnetometry. They display hydrodynamic diameters in the 100 nm range, zetapotential values around -30 mV, and magnetization values higher than the reference contrast agent RESOVIST®. They display no cytotoxicity against 1BR3G and HCT116 cell lines and no hemolytic activity against human red blood cells. Their nuclear magnetic relaxation dispersion (NMRD) profiles are typical for nanomaterials of this size and magnetization. They display high r2 relaxivity values and low r1 leading to enhanced r2/r1 ratios in comparison with RESOVIST®. All these data make them promising contrast agents to detect early stage tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Substrate specificity and structural modeling of human Carboxypeptidase Z, a unique protease with a Frizzled-like domain

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • García Guerrero, María del Carmen|||0000-0001-7651-7629
  • Dasgupta, Sayani
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Fricker, Lloyd D.
Metallocarboxypeptidase Z (CPZ) is a secreted enzyme that is distinguished from all other members of the M14 metallocarboxypeptidase family by the presence of an N-terminal cysteine-rich Frizzled-like (Fz) domain that binds Wnt proteins. Here, we present a comprehensive analysis of the enzymatic properties and substrate specificity of human CPZ. To investigate the enzymatic properties, we employed dansylated peptide substrates. For substrate specificity profiling, we generated two different large peptide libraries and employed isotopic labeling and quantitative mass spectrometry to study the substrate preference of this enzyme. Our findings revealed that CPZ has a strict requirement for substrates with C-terminal Arg or Lys at the P1' position. For the P1 position, CPZ was found to display specificity towards substrates with basic, small hydrophobic, or polar uncharged side chains. Deletion of the Fz domain did not affect CPZ activity as a carboxypeptidase. Finally, we modeled the structure of the Fz and catalytic domains of CPZ. Taken together, these studies provide the molecular elucidation of substrate recognition and specificity of the CPZ catalytic domain, as well as important insights into how the Fz domain binds Wnt proteins to modulate their functions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in parkinson's disease

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Novio, Fernando|||0000-0002-1517-3612
  • Nador, Fabiana|||0000-0003-2502-0430
  • Cavaliere, Ivana
  • Suárez García, Salvio|||0000-0002-4156-0579
  • Lope-Piedrafita, Silvia|||0000-0002-8127-6425
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Romero-Gimenez, Jordi
  • Rodríguez-Galván, Beatriz
  • Bové, Jordi|||0000-0002-2529-205X
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Dopamine (DA) is one of the main neurotransmitters found in the central nervous system and has a vital role in the function of dopaminergic (DArgic) neurons. A progressive loss of this specific subset of cells is one of the hallmarks of age-related neurodegenerative disorders such as Parkinson's disease (PD). Symptomatic therapy for PD has been centered in the precursor l-DOPA administration, an amino acid precursor of DA that crosses the blood-brain barrier (BBB) while DA does not, although this approach presents medium- to long-term side effects. To overcome this limitation, DA-nanoencapsulation therapies are actively being searched as an alternative for DA replacement. However, overcoming the low yield of encapsulation and/or poor biodistribution/bioavailability of DA is still a current challenge. Herein, we report the synthesis of a family of neuromelanin bioinspired polymeric nanoparticles. Our system is based on the encapsulation of DA within nanoparticles through its reversible coordination complexation to iron metal nodes polymerized with a bis-imidazol ligand. Our methodology, in addition to being simple and inexpensive, results in DA loading efficiencies of up to 60%. In vitro, DA nanoscale coordination polymers (DA-NCPs) exhibited lower toxicity, degradation kinetics, and enhanced uptake by BE(2)-M17 DArgic cells compared to free DA. Direct infusion of the particles in the ventricle of rats in vivo showed a rapid distribution within the brain of healthy rats, leading to an increase in striatal DA levels. More importantly, after 4 days of nasal administrations with DA-NCPs equivalent to 200 μg of the free drug per day, the number and duration of apomorphine-induced rotations was significantly lower from that in either vehicle or DA-treated rats performed for comparison purposes. Overall, this study demonstrates the advantages of using nanostructured DA for DA-replacement therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Copper(II) N, N, O -Chelating Complexes as Potential Anticancer Agents

  • Peña Aparicio, Joaquim|||0000-0001-6477-8127
  • Sciortino, Giuseppe|||0000-0001-9657-1788
  • Maréchal, Jean-Didier|||0000-0002-8344-9043
  • Bertaina, Sylvain|||0000-0002-6466-8830
  • Simaan, A. Jalila|||0000-0003-2537-0422
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Bayón, Pau|||0000-0002-3064-8866
  • Iranzo, Olga|||0000-0001-8542-2429
  • Palacios, Òscar|||0000-0002-2987-7303
Three novel dinuclear Cu(II) complexes based on a N,N,O-chelating salphen-like ligand scaffold and bearing varying aromatic substituents (-H, -Cl, and -Br) have been synthesized and characterized. The experimental and computational data obtained suggest that all three complexes exist in the dimeric form in the solid state and adopt the same conformation. The mass spectrometry and electron paramagnetic resonance results indicate that the dimeric structure coexists with the monomeric form in solution upon solvent (dimethyl sulfoxide and water) coordination. The three synthesized Cu(II) complexes exhibit high potentiality as ROS generators, with the Cu(II)/Cu(I) redox potential inside the biological redox window, and thus being able to biologically undergo Cu(II)/Cu(I) redox cycling. The formation of ROS is one of the most promising reported cell death mechanisms for metal complexes to offer an inherent selectivity to cancer cells. In vitro cytotoxic studies in two different cancer cell lines (HeLa and MCF7) and in a normal fibroblast cell line show promising selective cytotoxicity for cancer cells (IC50 about 25 μM in HeLa cells, which is in the range of cisplatin and improved with respect to carboplatin), hence placing this N,N,O-chelating salphen-like metallic core as a promising scaffold to be explored in the design of future tailor-made Cu(II) cytotoxic compounds.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment

  • Mao, Xiaoman
  • Wu, Shuang|||0000-0001-7618-5476
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Glioblastoma is the most malignant and frequently occurring type of brain tumors in adults. Its treatment has been greatly hampered by the difficulty to achieve effective therapeutic concentration in the tumor sites due to its location and the blood-brain barrier. Intranasal administration has emerged as an alternative for drug delivery into the brain though mucopenetration, and rapid mucociliary clearance still remains an issue to be solved before its implementation. To address these issues, based on the intriguing properties of proteins secreted by mussels, polyphenol and catechol functionalization has already been used to promote mucopenetration, intranasal delivery and transport across the blood-brain barrier. Thus, herein we report the synthesis and study of complex 1, a Pt(IV) prodrug functionalized with catecholic moieties. This complex considerably augmented solubility in contrast to cisplatin and showed a comparable cytotoxic effect on cisplatin in HeLa, 1Br3G and GL261 cells. Furthermore, preclinical in vivo therapy using the intranasal administration route suggested that it can reach the brain and inhibit the growth of orthotopic GL261 glioblastoma. These results open new opportunities for catechol-bearing anticancer prodrugs in the treatment for brain tumors via intranasal administration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Study and Preparation of Multifunctional Poly(L-Lysine)@Hyaluronic Acid Nanopolyplexes for the Effective Delivery of Tumor Suppressive MiR-34a into Triple-Negative Breast Cancer Cells

  • Djafari, Jamila|||0000-0003-2817-0338
  • Fernández-Lodeiro, Javier|||0000-0001-8853-2631
  • Santos, Hugo M.|||0000-0002-6032-8679
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Bértolo, Emilia|||0000-0002-1633-8212
  • Capelo-Martínez, José Luis|||0000-0001-6276-8507
  • Lodeiro, Carlos|||0000-0001-5582-5446
Non-viral gene delivery using exogenous microRNAs is a potential strategy for fighting cancers with poor prognosis and which lack specific therapies, such as triple-negative breast cancer (TNBC). Herein we report the synthesis of six nontoxic electrostatic polymeric nanocapsules (P1 to P6) for microRNA delivery in TNBC cells. 1H Nuclear Magnetic Resonance (NMR) spectroscopy and Scanning Electron Microscopy (SEM) were used to characterize the nanopolyplexes, synthesized with Poly(L-Lysine) and hyaluronic acid (Ha). Studies on the activity of the ternary HA/PLI/miRNA-34 nanopolyplexes towards TNBC cell line MDA-MB-231 were conducted. The nanopolyplexes mediated intracellular restoration of tumor suppressor miR34a was evaluated by using Western blotting to quantify the expression level of the Bcl-2 protein. The results suggest that the P5, with a ratio PLI/Ha of 0.05, was the most promising for the delivery of miR-34a into TNBC cells; the P5 nanocapsules were able to reduce Bcl-2 expression at a protein level, and had an effect in the overall cell viability after 24 h treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy

  • Mao, Xiaoman
  • Calero-Perez, Pilar|||0000-0001-9370-3757
  • Montpeyó, David|||0000-0002-0327-2015
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Novio, Fernando|||0000-0002-1517-3612
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Cisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH- and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis and In Vitro Studies of Photoactivatable Semisquaraine-type Pt(II) Complexes

  • Morales Fernández, Kevin|||0000-0001-6096-7174
  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Hernando, Jordi|||0000-0002-1126-4138
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Rodríguez-Diéguez, Antonio|||0000-0003-3198-5378
  • Jaime, Carlos|||0000-0002-9690-9053
  • Nolis, Pau|||0000-0003-2360-1709
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Palacios, Òscar|||0000-0002-2987-7303
  • Figueredo Galimany, Marta|||0000-0002-8278-7534
  • Bayón, Pau|||0000-0002-3064-8866
The synthesis, full characterization, photochemical properties, and cytotoxic activity toward cisplatin-resistant cancer cell lines of new semisquaraine-type Pt(II) complexes are presented. The synthesis of eight semisquaraine-type ligands has been carried out by means of an innovative, straightforward methodology. A thorough structural NMR and X-ray diffraction analysis of the new ligands and complexes has been done. Density functional theory calculations have allowed to assign the trans configuration of the platinum center. Through the structural modification of the ligands, it has been possible to synthesize some complexes, which have turned out to be photoactive at wavelengths that allow their activation in cell cultures and, importantly, two of them show remarkable solubility in biological media. Photodegradation processes have been studied in depth, including the structural identification of photoproducts, thus justifying the changes observed after irradiation. From biological assessment, complexes C7 and C8 have been demonstrated to behave as promising photoactivatable compounds in the assayed cancer cell lines. Upon photoactivation, both complexes are capable of inducing a higher cytotoxic effect on the tested cells compared with nonphotoactivated compounds. Among the observed results, it is remarkable to note that C7 showed a PI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhanced Production of ECM Proteins for Pharmaceutical Applications Using Mammalian Cells and Sodium Heparin Supplementation

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Montané, Sergi|||0000-0002-8855-5662
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
The yields of soluble ECM proteins recombinantly produced with mammalian cells can be significantly enhanced by exploiting the stabilizing properties of heparin. Here, we propose a simple and straightforward scalable protocol for the mammalian cell production of ECM proteins with affinity for heparin, using heparin as a supplement. As proof of concept, we have demonstrated the high-level expression of four biomedically relevant human enzymes such as carboxypeptidase Z (CPZ), carboxypeptidase A6 (CPA6), beta-galactoside alpha-2,6-sialyltransferase 2 (ST6GAL1) and thrombin-activable fibrinolysis inhibitor (TAFI). We found a strong linear correlation between the isoelectric point (pI) of a protein and the improvement in protein expression levels upon heparin addition, providing a reference for selecting novel protein targets that would benefit from heparin supplementation. Finally, we demonstrated the compatibility of this approach with a three-step purification strategy that includes an initial heparin affinity purification step. Using CPZ as a representative example, we performed a preparative purification of this enzyme. The purified protein is enzymatically active and can be used for pharmaceutical applications as well as for high-throughput functional and structural studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy

  • Peña Aparicio, Joaquim|||0000-0001-6477-8127
  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Simaan, A. Jalila|||0000-0003-2537-0422
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Bayón, Joan Carles|||0000-0002-2498-1945
  • Palacios, Òscar|||0000-0002-2987-7303
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Iranzo, Olga|||0000-0001-8542-2429
Metal-based chemotherapeutics like cisplatin are widely employed in cancer treatment. In the last years, the design of redox-active (transition) metal complexes, such as of copper (Cu), has attracted high interest as alternatives to overcome platinum-induced side-effects. However, several challenges are still faced, including optimal aqueous solubility and efficient intracellular delivery, and strategies like the use of cell-penetrating peptides have been encouraging. In this context, we previously designed a Cu(II) scaffold that exhibited significant reactive oxygen species (ROS)-mediated cytotoxicity. Herein, we build upon the promising Cu(II) redox-active metallic core and aim to potentiate its anticancer activity by rationally tailoring it with solubility- and uptake-enhancing functionalizations that do not alter the ROS-generating Cu(II) center. To this end, sulfonate, arginine and arginine-rich cell-penetrating peptide (CPP) derivatives have been prepared and characterized, and all the resulting complexes preserved the parent Cu(II) coordination core, thereby maintaining its reported redox capabilities. Comparative in vitro assays in several cancer cell lines reveal that while specific solubility-targeting derivatizations (i.e., sulfonate or arginine) did not translate into an improved cytotoxicity, increased intracellular copper delivery via CPP-conjugation promoted an enhanced anticancer activity, already detectable at short treatment times. Additionally, immunofluorescence assays show that the Cu(II) peptide-conjugate distributed throughout the cytosol without lysosomal colocalization, suggesting potential avoidance of endosomal entrapment. Overall, the systematic exploration of the tailored modifications enables us to provide further understanding on structure-activity relationships of redox-active metal-based (Cu(II)) cytotoxic complexes, which contributes to rationalize and improve the design of more efficient redox-mediated metal-based anticancer therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Advances in preclinical/clinical glioblastoma treatment, can nanoparticles be of help?

  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Mao, Xiaoman
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Bruna, Jordi|||0000-0001-6895-5047
  • Yuste, Victor José|||0000-0001-5322-9261
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Novio, Fernando|||0000-0002-1517-3612
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Roadmap on nanomedicine for the central nervous system

  • Ciofani, Gianni|||0000-0003-1192-3647
  • Campisi, Marco
  • Mattu, Clara
  • Kamm, Roger D.|||0000-0002-7232-304X
  • Chiono, Valeria|||0000-0003-2067-7732
  • Raynold, Aji Alex Moothedathu
  • Freitas, João S.
  • Redolfi Riva, Eugenio
  • Micera, Silvestro|||0000-0003-4396-8217
  • Pucci, Carlotta
  • Novio, Fernando|||0000-0002-1517-3612
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Sierri, Giulia
  • Re, Francesca
  • Wunderlich, Hannah
  • Kumari, Prachi
  • Kozielski, Kristen L.|||0000-0003-3504-2318
  • Chami, Mounia|||0000-0003-1498-7187
  • Marino, Attilio
  • Ferreira, Lino|||0000-0001-8985-9302
In recent years, a great deal of effort has been undertaken with regards to treatment of pathologies at the level of the central nervous system (CNS). Here, the presence of the blood-brain barrier acts as an obstacle to the delivery of potentially effective drugs and makes accessibility to, and treatment of, the CNS one of the most significant challenges in medicine. In this Roadmap article, we present the status of the timeliest developments in the field, and identify the outstanding challenges and opportunities that exist. The format of the Roadmap, whereby experts in each discipline share their viewpoint and present their vision, reflects the dynamic and multidisciplinary nature of this research area, and is intended to generate dialogue and collaboration across traditional subject areas. It is stressed here that this article is not intended to act as a comprehensive review article, but rather an up-to-date and forward-looking summary of research methodologies pertaining to the treatment of pathologies at the level of the CNS.